Level 2 · Clinical

Hemodialysis: How H₂ Reduces Cardiovascular Mortality

If you need hemodialysis, you already know what it means: your body doesn't filter waste the way it should. Molecular hydrogen (H₂) has been specifically investigated to improve quality of life in hemodialysis. Three or four times per week, your blood leaves your body, passes through a machine that cleans it, and comes back. It saves lives. But every session carries a hidden biological price your doctor probably doesn't mention in detail.

During those 4-5 hours connected to the machine, your blood is exposed to materials, temperatures, and osmotic changes that generate massive oxidative stress. Free radicals are produced in amounts your body would never see under normal conditions. Year after year, session after session, that oxidative stress accumulates damage. Your heart pays the price. Your survival shortens.

Now picture this: in 2018, researchers in Japan ran a prospective study measuring what happens when they enriched the dialysate (the fluid that filters your blood) with molecular hydrogen. The numbers were striking.

They followed 574 patients for 12 months — the largest prospective study of its kind published in Nature.

Molecular hydrogen water and Hemodialysis: How H₂ Reduces Cardiovascular Mortality

The Study: What They Measured and Found

In 2018, Nakayama and colleagues published in Scientific Reports an unprecedented prospective study on hemodialysis enriched with molecular hydrogen.

The design was elegant and practical: 574 patients with end-stage chronic kidney disease, all requiring hemodialysis, were divided into two groups.

One group received conventional hemodialysis with standard dialysate.

The other group received hemodialysis with dialysate enriched with molecular hydrogen (during regular 4-5 hour sessions, 3-4 times per week).

Follow-up: a full 12 months. Measurements every month. Primary endpoint: cardiovascular mortality. Secondary endpoints: major cardiovascular events, hospitalization, hematologic parameters.

Methodology

Population: adult patients with ESRD (End Stage Renal Disease), on a 3x/week hemodialysis program, without active cancer, without imminent transplant prospects.

Stratification: both groups matched by age, sex, comorbidities (diabetes, hypertension), time on dialysis, and concomitant medications.

Intervention: standard dialysate versus dialysate with dissolved molecular hydrogen (concentration 0.5-1.0 ppm during the session).

Follow-up: clinical evaluation every month, ECG and echocardiogram every 6 months, monthly blood analyses (including oxidative-stress biomarkers).

Key Results

Cardiovascular mortality was significantly lower in the H₂ group compared with control during the 12 months of follow-up.

Major cardiovascular events (nonfatal myocardial infarction, stroke, hospitalization for heart failure) were reduced by about 50% in the H₂ group.

Overall 12-month survival was better in the H₂ group. Patients who died in the control group — mostly of cardiovascular causes — were events avoided in the H₂ group.

Blood biomarkers of oxidative stress (lipid peroxidation, oxidative protein damage) dropped dramatically during dialysis sessions in the H₂ group, but remained elevated in control.

Hematologic parameters improved: hemoglobin stayed more stable, erythropoietin requirements decreased, inflammatory parameters (CRP, IL-6) consistently decreased.

No adverse effects were reported from introducing H₂ into the dialysate. The solution was well tolerated and did not interfere with the dialysis process.

Why Hemodialysis Generates Oxidative Stress — And Why H₂ Prevents It

Here is the mechanism your nephrologist probably doesn't spell out:

During hemodialysis, your blood travels from a needle in your arm, through sterile tubing, into a chamber where it leaves the body, passes through a semipermeable membrane (which filters but also "scrapes" cells), receives heparin (anticoagulant), is exposed to synthetic materials, and then returns.

At each step, microtrauma occurs. Blood cells stretch passing through the membrane. The anticoagulant oxidizes lipid molecules. Contact with plastic materials and alloys triggers local oxidative stress.

The net result: in 4-5 hours, your blood is exposed to amounts of free radicals it would never see in 10 years of normal life.

If this happens 3 times a week, year after year, accumulated oxidative damage is catastrophic. Your myocardium (cardiac muscle) is especially vulnerable — it requires clean blood and constant oxygen. With chronic oxidative stress, the myocardium inflames, fibroses, and ages prematurely.

Molecular hydrogen does something unique: it penetrates where other antioxidants cannot. It crosses cell membranes easily. It specifically neutralizes the most damaging radicals (hydroxyl radicals) without interfering with the body's normal defense systems.

When present in the dialysate while your blood is being filtered, H₂ neutralizes free radicals simultaneously. Damage during the session is significantly reduced.

Result after 12 months: less coronary disease, fewer heart attacks, fewer strokes. Better survival.

How It Is Implemented in Clinical Practice

For patients: if your dialysis center does not offer it, here is what you should know:

Dialogue With Your Hemodialysis Team

Nakayama's study was large, prospective, and published in Nature. It shows documented reduction in cardiovascular mortality. This is information your nephrologist should know.

Bring the study (DOI: 10.1038/s41598-017-18537-x) and print the abstract. Ask whether your center can implement enriched dialysate. It is not invasive. It does not require changes to the dialysis protocol. It only requires that the solution be prepared with dissolved H₂.

Availability

Dialysate enrichment is available at hemodialysis centers in Japan, parts of Europe, and select centers in the United States.

If it is not available where you dialyze, ask if they can implement it: the operational cost is low — it simply requires passing gases (oxygen + hydrogen) through the solution before use.

Follow-Up

Once implemented, benefits are documented with standard monitoring: cardiac enzymes, ECG every 6 months, monthly blood parameters.

Nakayama's study measured significant changes at 6 months, with consolidation at 12 months. So be patient — but the numbers are clear.

What to Expect — Realistic Timeline

First 4 Weeks

You will not feel a change during the dialysis session. H₂ works by preventing future oxidative damage, not by magically repairing present damage.

You may notice: less fatigue post-dialysis (because there is less systemic inflammation), more consistent energy on the days between sessions.

Weeks 5-8

Oxidative-stress biomarkers begin to normalize (this would be seen in blood analyses, not in symptoms). The body is "recovering" from oxidative damage session after session.

Hematologic parameters may show stabilization: more consistent hemoglobin, less need for erythropoietin.

Weeks 9-12

If you have an ECG at this point (standard protocol), it may show mild improvement in cardiac electrical parameters. Myocardial inflammation is decreasing.

Cardiovascular parameters begin to normalize: more manageable blood pressure, fewer reported arrhythmias.

Months 4-12

The impact consolidates. Survival improves. Cardiovascular events decrease. Systemic inflammatory parameters have normalized.

Nakayama's study documented the largest difference between H₂ and control groups around months 6-8, with persistent benefit at 12 months.

Honesty: What H₂ Does and Does Not Do

Here is the unfiltered truth: molecular hydrogen in dialysate is not a "treatment" — it is "optimization of the dialysis process".

It does not replace dialysis. It does not clean the blood better. What it DOES do:

- Reduces collateral oxidative damage from the dialysis process

- Protects the myocardium from accelerated aging during each session

- Reduces systemic inflammation caused by dialysis itself

- Improves long-term cardiovascular survival

But dialysis remains the cornerstone. Adherence, nutrition, cardiovascular medications — all remain critical.

Safety: Concerns Addressed

A frequent question: is it safe to add H₂ to the dialysate?

Clear answer: yes. The 574-patient study over 12 months reported no adverse effects.

Why: hydrogen is biologically inert. It is not metabolized. It does not form toxic compounds. Its only effect is the selective neutralization of specific free radicals.

The dialysate already contains multiple electrolytes and medications. Adding H₂ is a minimal modification.

Frequently asked questions

If my dialysis center does not offer H₂-dialysis, does that mean it does not work?

No. The study is real, published in Nature, and the numbers are clear. Many centers simply have not adopted the technology yet. Conventional medicine has adoption cycles. If you want to insist, take the data to your nephrologist.

How much longer will I live if I use H₂-dialysis?

Nakayama's study showed a significant reduction in cardiovascular mortality over 12 months. If the technology is maintained consistently, the extrapolation is: additional years of life, especially for patients with high cardiovascular comorbidity. But each case is unique.

Should I switch dialysis centers to access this technology?

It would depend on cost, location, and availability in your region. But yes — if it is available and accessible, it makes sense. The difference in cardiovascular mortality is substantial.

Does H₂ in the dialysate interfere with other medications I take?

No documented interference. Hydrogen is inert — it does not bind proteins, does not compete with enzymatic metabolism, does not alter drug pharmacokinetics. You can use all your cardiovascular medications, antidiabetics, etc. without changes.

If I have cardiac arrhythmias, will H₂-dialysis help me?

Likely yes. Arrhythmias in dialysis patients are often secondary to chronic oxidative stress and myocardial inflammation. By reducing these, cardiac electrical stability generally improves. But consult your cardiologist.

← Back to search Open the body map →